From: Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B
Cell Line
GrB-Fc-4D5 IC50 (nM)
Kadcyla IC50 (nM)
Log phase
Confluent
SKBR3
56
64
< 0.04
HT-29
36
127
41
121
MDA-MB-231
27
58
44
79
A-549
55
68
78
76
DU-145
13
25
125
205